Four months vitamin D supplementation to vitamin D insufficient individuals does not improve muscular strength: A randomized controlled trial

Guri Grimnes [1,2] *, Julia Kubiak[1,2], Rolf Jorde[1,2]

1 Tromsø Endocrine Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway, 2 Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway

* guri.grimnes@unn.no

Abstract

Main objective

The inconsistent results on the effects of vitamin D on muscle strength reported by intervention trials may partly be explained by inclusion of vitamin D sufficient individuals. The main objective was to study whether vitamin D supplementation will improve muscle strength in men and women with low serum vitamin D status, as measured by 25-hydroxyvitamin D (25 (OH)D) at baseline.

Methods

417 men and women aged 40–80 years were included and randomized to receive a loading dose of 100 000 IU (2500 ug) vitamin D_3 followed by 20 000 IU (500 ug)/week, or placebo. Muscle strength was tested by dynamometers at baseline and after four months.

Results

Serum 25(OH)D levels increased from 32.6±11.1 nmol/l to 88.8±19.4 nmol/l (p<0.01) in the vitamin D group, while remaining low in the placebo group (baseline and final levels at 35.1 ±13.6 nmol/l and 30.7 ±9.7 nmol/l respectively). Muscle strength (hip flexion, biceps flexion, pectorals and handgrip strength) did not change in any of the groups. The results were the same in analyses stratified on sex, 25(OH)D above/below 25 nmol/L (10 ng/ml); smoking status; and BMI above/below 27 kg/m^2.

Conclusion

These data does not support vitamin D supplementation for improving muscle strength.

Introduction

Vitamin D deficiency is common [1], and associated with numerous negative health outcomes
[2]. In particular, vitamin D is important for skeletal health, as deficiency may lead to rickets
or osteomalacia [3]. The effects of vitamin D on fractures and falls have recently been ques-
tioned [4].

Muscle weakness and pain are commonly seen in osteomalacia [5], vitamin D receptors are
present in muscle cells [6,7], and several observational studies have reported inverse associa-
tions between serum 25-hydroxyvitamin D (25(OH)D) levels and muscle strength [8,9]. Possi-
ble mechanisms include changes in muscle morphology (with atrophy of type 2 muscle fibers
[10] as well as increased fatty infiltration in skeletal muscle [11]), improved mitochondrial
function with vitamin D supplementation [12], and by optimizing contractility through regu-
lation of calcium and phosphate handling [13]. Taking these results into account, one could
expect an effect on muscle strength and function with vitamin D supplementation, but as the
results from randomized controlled trials (RCTs) have been inconsistent, meta-analyses have
concluded differently [14,15]. Thus, Beaudart et al. reported in 2014 in a systematic review and
meta-analysis of RCTs using vitamin D a small, but significant effect of vitamin D supplemen-
tation on global muscle strength, which was more evident in people with 25(OH)D < 30
nmol/l as well as in people ≥ 65 years of age [14]. On the other hand, no effect was found in a
similar systematic review and meta-analyses by Rosenahl-Riise et al. in 2017 [15].

Some of the heterogeneity of the results may be a reflection of different study designs,
where a common pitfall is to include participants with sufficient vitamin D status (measured
as 25-hydroxyvitamin D (25(OH)D)) at baseline [16,17]. Another limitation of the available
studies, is that most of them are performed only with women [15].

We had the opportunity to include healthy community-dwelling participants of both gen-
ders and with low basal serum 25(OH)D levels from a large population-based study, in a ran-
domized controlled trial with vitamin D supplementation over four months, assessing changes
in standardized measurements of muscle strength. We hypothesized that vitamin D supple-
mentation to vitamin D insufficient persons would improve muscle strength as compared to
placebo.

Material and methods

Subjects

The Tromsø study is a population based health survey that was first conducted in 1974 [18].
In the seventh wave in 2015/2016, all citizens aged 40 years and older (n = 32 591) living in
the municipality of Tromsø in northern Norway were invited to participate, where 21 083
attended. Serum 25(OH)D was measured on an ongoing basis in a total of 20922 participants,
and based on the distribution, those with levels below the 7th percentile (<42 nmol/L (16.8
ng/ml)) and age <80 years were invited to participate in this study. Of 1489 subjects invited,
639 responded positively and were phone screened by the study nurses from the Clinical
Research Unit at the University Hospital of North Norway. A standardized medical interview
was performed in order to exclude subjects with known granulomatous disease, renal stones
last five years, or serious diseases apparent through interview or screening blood tests that
would make the subject unfit for participation. Patients with diabetes were excluded from par-
ticipation due to one of the primary outcomes insulin resistance. Additionally, subjects with
use of vitamin D supplements exceeding 800 IU (20 ug) vitamin D per day, subjects who used
solarium on a regular basis, or were planning holiday(s) in tropical areas during the study
period were excluded from participation. Women of childbearing potential (below the age of

50 years) without use of contraception were excluded. Weight and height and smoking status were asked for and used in the randomization procedure.

Study design

The main end point of the study was effects on cardio-vascular risk factors, and the study design has been described in detail elsewhere [19]. In short, those who fulfilled the inclusion criteria, came to the first visit at the Clinical Research Unit of the University Hospital of North Norway for signing of the informed consent form, clinical examinations, height and weight measurements wearing light clothing and no shoes, medical history and fasting blood samples which included hemoglobin, liver enzymes, calcium, creatinine, thyroid hormones and TSH, high-sensitive CRP, sedimentation rate and glycated hemoglobin. If these examinations did not reveal any contraindication for participation, the next visit was performed within 2–5 days. At this second visit, the muscle strength testing was performed and the study drugs (20 000 IU (500 ug) cholecalciferol capsules Dekristol, Mibe, Jena, Germany) or identical looking placebo capsules containing arachis oil (Hasco-Lek, Wroclaw, Poland) were dispensed. Five capsules were given as a loading dose, followed by one capsule each week. The subjects were asked not to take any vitamin D supplements (including cod liver oil) during the four months intervention period.

The randomization was stratified according to gender, vitamin D status in the Tromsø study (serum 25(OH)D above/below 25 nmol/L (10 ng/ml)), smoking status (current smoking or not) and BMI above/below 27 kg/m^2 (self-reported height and weight). Based on this, the randomization unit assigned the subject a randomization number using a block randomization procedure with random block sizes of 2, 4 or 6. This number was sent to the Clinical Research Unit (who did not have the randomization key) and to the hospital's pharmacy (who had the key), with the latter dispensing the medication accordingly. Except for the pharmacy, which had no contact with the study participants, all nurses, doctors, other study personnel and study participants were blinded for the randomization throughout the study.

Two months after inclusion, a study nurse contacted the participants by phone to ask for adverse events and remind them to take the study medication. At four months the third visit was performed with examinations identical to the first visit. The fourth visit followed a few days later, with return of study medication and examinations identical to the second visit. Compliance was calculated as the ratio between capsules used (capsules supplied minus capsules returned) and number of weeks between second and fourth visit.

Muscle strength testing

Handgrip strength was measured using a Jamar Plus dynamometer (Jamar Technologies, Lakewood, NJ, USA). The dominant side was used, but if there was a known injury or functional loss in the dominant side, the non-dominant side was preferred, also for the repeated final examination. Hip flexion strength, pectoralis strength and biceps strength were measured by use of the hand-held dynamometer Jtech Commander Muscle Tester (Jtech Medical Industries, Midvale, Utah, USA). Use of hand-held dynamometry have been shown to be a reliable and valid instrument for muscle strength testing as compared to the gold standard isokinetic dynamometry [20]. Standardized procedures were followed, with detailed description of how to place and stabilize the patient in order to isolate the muscle group being tested. External belt-fixation was used for hip and elbow flexion in order to avoid impact from the strength of the research nurse [21]. The participants were carefully instructed how to perform the tests. The participant was asked to press maximally towards the fixed dynamometer for three seconds. The study nurse counted 1-2-3 before starting, and also told the participant when to

stop. Each test was performed three times with 30 seconds rest in-between, and the highest of the three measurements was used in the analyses.

Laboratory measurements

Serum 25(OH)D was measured by an in-house developed liquid chromatography–tandem mass spectrometry method that detects both 25(OH)D$_3$ and 25(OH)D$_2$, as well as the sum of these presented as 25(OH)D in the results [22]. The laboratory takes part in the external quality program DEQAS. Plasma parathyroid hormone (PTH) was analyzed with an electrochemi-lumniscence immunoassay (ECLIA) using an automated clinical chemistry analyzer (Cobas 6000, Roche) with a reference range of 1.1–6.8 pmol/L for those <50 years and 1.1–7.5 pmol/L for those >50 years. Serum calcium was analyzed by an automated analyzer (Modular P, Roche Diagnostics, Mannheim, Germany).

Statistical methods and power calculation

We used the statistical software package SPSS version 22. Descriptive results are shown as mean±SD if not stated otherwise. Normal distribution was evaluated by visual inspection of plots, and although there was some skewness and curtosis present, parametric tests were considered appropriate due to the large sample size. The end points were changes in muscle strength (delta strength) between the beginning and the end of the study (second and fourth visit), which was calculated separately for each participant. Independent t-tests were used for between-groups comparisons of delta strength for biceps, hip flexion, hand grip and pectoralis, as well as serum 25(OH)D, calcium and plasma PTH. Sensitivity analyses were performed in strata according to the randomization factors gender; vitamin D status in the Tromsø study (serum 25(OH)D above/below 25 nmol/L (10 ng/ml)); smoking status; and BMI above/below 27 kg/m^2.

The power was calculated based on the main end point of the study, cardiovascular risk factors. The effect of vitamin D supplementation was assumed to be about two-third of the observed difference in cross-sectional studies between people with serum 25(OH)D levels of 30 and 80 nmol/l. Accordingly, between 300 and 500 participants were needed to attain a power of 0.8 and p<0.05 to detect a difference of 6.7 mmHg in systolic blood pressure, 3.3 mmHg in diastolic pressure, 0.26 mmol/l in triglycerides, 0.09 mmol/l in HDL-cholesterol and 0.57 in HOMA-IR. To account for an assumed drop-put rate of 16%, the aim was to include 600 subjects [19].

Ethics

The study was approved by the Regional Committee for Medical Research Ethics (REK NORD 2013/1464) 4th of September 2014 and by the Norwegian Medicines Agency (2013-003514-40). The study is registered at ClinicalTrials.gov NCT02750293. Due to a misunderstanding the study was registered there shortly after the first subject was included. The authors confirm that all ongoing and related trials for this drug/intervention are registered. The inclusion started 2nd of June 2015, and last visit was performed 27th of April 2017. All subjects gave their written informed consent.

Results

Of the 639 participants screened by phone, 455 attended the first visit with clinical examination and blood sampling. Thirty-three participants did not fulfill the inclusion criteria, and consequently 422 met to the second visit, and were randomized to vitamin D or placebo, one

Fig 1. Flow chart of the inclusion of participants.

without successfully performed muscle testing. During the study, three participants withdrew their consent, and seven were excluded due to intercurrent disease or medication use not suitable with continuation. Thus, 411 completed the study and were included in the present analyses (Fig 1). Their baseline characteristics are presented in Table 1. Those randomized to vitamin D had a slightly lower 25(OH)D at baseline. Delta values for muscle strength, 25(OH)

Table 1. Baseline characteristics of the study population.

	Vitamin D	Placebo
n	208	203
Age (years)	51.5±8.6	52.6±8.7
Females (percentage)	46.6	46.8
BMI (kg/m^2)	27.9±5.1	27.8±4.7
Serum 25(OH)D (nmol/L)*	32.6±11.1	35.1±13.6
Plasma PTH (pmol/L)	6.7±2.2	6.8±1.9
Serum calcium (mmol/L)	2.27±0.07	2.27±0.07
Smokers (percentage)	22.1	22.2
Hip flexion (N)	181.2±63.8	175.0±61.8
Biceps flexion (N)	129.5±66.8	129.4±66.8
Pectoralis (N)	307.7±137.3	306.0±138.5
Hand grip (kg)	41.8±11.6	41.9±12.7

N; Newton

Data are mean±SD if not stated otherwise.

*P for difference <0.05

D, PTH and calcium levels are shown in Table 2 and compared between the treatment groups. Serum 25(OH)D increased significantly, accompanied by a significant decrease in PTH and a slight increase in serum calcium in the vitamin D group as compared to the placebo group. However, changes in muscle strength did not differ significant between the groups. The results for changes in muscle strength were the same in the sensitivity analyses in strata of gender; vitamin D; smoking status; and BMI as shown in Table 3.

The compliance to the study medication regimen was 100% in 86% of the participants, and above 84% in all. No serious study-related side effects were recorded. Two participants developed slight hypercalcemia; one male whose serum calcium normalized upon retesting, and one female who had developed primary hyperparathyroidism.

Discussion

In this randomized controlled trial including adults with low serum 25(OH)D levels, no effects on muscular strength were observed after four months administration of vitamin D versus placebo. There were no gender differences.

Table 2. Changes in muscular strength during intervention.

	Vitamin D		Placebo		P for difference in change between groups
	n	Change	n	Change	
Hip flexion (N)	206	-0.6±49.9	198	-2.8±42.3	0.64
Biceps flexion (N)	206	5.2±49.3	198	1.2±51.1	0.43
Pectoralis (N)	205	18.4±83.4	197	11.9±82.6	0.43
Hand grip (kg)	206	1.0±4.2	199	0.5±4.3	0.31
25(OH)D (nmol/L)	208	56.2±22.2	203	-4.5±12.8	<0.01
Plasma PTH (pmol/L)	208	-0.8±1.4	203	0.5±1.5	<0.01
Serum calcium (mmol/L)	208	0.01±0.07	203	0.00±0.06	<0.01

N, Newton

Data are mean±SD.

Table 3. Changes in muscular strength during intervention. Stratified analyses.

	Vitamin D		Placebo		P for difference in change between groups	Vitamin D		Placebo		P for difference in change between groups
	n	change	n	change		n	change	n	change	
	Female					**Male**				
Hip flexion (N)	95	3.1±62.8	93	2.6±36.7	0.95	111	-2.8 ±62.5	105	-7.5±46.4	0.53
Biceps flexion (N)	95	5.2±29.7	93	12.9 ±36.0	0.11	111	5.1±61.5	105	-9.2±59.8	0.09
Pectoralis (N)	94	21.2 ±62.8	93	15.6 ±72.5	0.58	111	16.1 ±97.7	104	8.6±90.8	0.56
Hand grip (kg)	96	1.1±4.2	93	0.9±3.6	0.67	110	0.9±4.2	106	0.3±4.8	0.33
	Serum 25(OH)D ≤25 nmol/l					**Serum 25(OH)D>25 nmol/l**				
Hip flexion (N)	46	-1.0 ±57.9	44	-7.8 ±36.0	0.51	160	0.2±64.0	154	-1.3±43.9	0.80
Biceps flexion (N)	47	1.8±46.1	44	3.5±43.3	0.86	159	6.1±50.3	154	0.6±53.2	0.34
Pectoralis (N)	47	13.3 ±98.1	45	3.0±91.0	0.60	158	19.9 ±78.7	152	14.6±80.0	0.55
Hand grip (kg)	47	1.2±3.7	45	0.0±4.1	0.18	159	0.9±4.4	154	0.7±4.4	0.63
	Non-smokers					**Smokers**				
Hip flexion (N)	160	1.7±65.4	155	-5.1 ±39.3	0.26	46	-6.2 ±51.5	43	5.6±51.3	0.28
Biceps flexion (N)	161	6.8±49.2	155	-1.8 ±52.8	0.13	45	-0.7 ±49.8	43	12.2±43.5	0.20
Pectoralis (N)	160	22.2 ±74.9	155	19.8 ±83.4	0.79	45	5.1 ±108.3	42	-17.0 ±73.4	0.27
Hand grip (kg)	161	0.9±4.2	156	0.6±4.3	0.67	45	1.4±4.2	43	0.2±4.4	0.17
	BMI<27 kg/m³					**BMI≥27kg/m³**				
Hip flexion (N)	99	-3.1 ±78.1	96	0.7±46.9	0.68	105	2.6±44.0	102	-6.1±37.3	0.13
Biceps flexion (N)	99	6.1±52.1	93	1.4±52.5	0.53	105	4.5±47.3	105	1.1±50.1	0.61
Pectoralis (N)	99	12.0 ±92.7	92	9.1±78.5	0.82	104	24.3 ±74.2	105	14.4±86.3	0.38
Hand grip (kg)	100	1.0±3.7	94	0.5±4.1	0.39	105	0.8±4.6	105	0.6±4.5	0.67

N, Newton

Data are mean±SD.

These results are in contrast to a meta-analysis and review from 2014 concluding with a weak, but positive, effect on muscle strength with vitamin D supplementation [14]. The effect was only evident in persons aged 65 years or older, and the discrepancy with our results may therefore be explained by inclusion of younger persons in our study, with few participants >65 years of age (<10%). The expression of VDRs in muscle is reported to decrease with age [7], and therefore older people might be more vulnerable to vitamin D insufficiency. In a paper published after the meta-analysis, a risk reduction of nearly 50% for injurious falls needing medical attention was reported in a two year follow-up period after a two years intervention trial with vitamin D in older women [23]. However, in a recent nine months vitamin D intervention trial in older men with baseline 25(OH)D levels >60 nmol/l, no effects on gait speed or Short Physical Performance Battery were observed [24]. Another study found no effect on handgrip strength or Timed Up and Go in elderly people after administration of 12000, 24000 or 48000 IU/month cholecalciferol, for one year [25]. However, there was no placebo group.

Finally, unfavorable effects on muscle strength were reported in elderly women randomized to receive 2800 IU/day cholecalciferol as compared to placebo for three months in a Danish study [26].

Several studies show that an effect of vitamin D supplementation on muscle strength is evident only in persons with serum 25(OH)D <30 nmol/l [14,27]. In contrast, we did not observe any effects in our subgroup of participants with baseline levels below a similar threshold (25 nmol/l), which is in accordance with another recently published meta-analysis which reported stronger effects of vitamin D supplementation on handgrip strength after exclusion of three studies with low baseline 25(OH)D levels. The authors speculated that the low levels represented patients with a higher degree of frailty, where it was too late to improve muscle strength [15]. In our study, the participants were community-dwelling, middle-aged people, recruited through a health survey, which are generally prone to healthy user bias. Also, only ten of the participants had sarcopenia as defined as maximal grip strength < 20 kg for women and 30 kg for men at baseline [28]. We therefore find it unlikely that the lack of effect could be explained by our participants being too frail to improve their muscle strength.

The effects of vitamin D may be dependent on interplay with factors like other conutrients [16], in particular calcium intake. Unfortunately, we did not have information regarding diet and calcium intake, but in general, the calcium intake in Scandinavian countries is high [29], and it might be that the threshold for clinical vitamin D deficiency is shifted downwards in such circumstances [30]. Also, some studies suggest that physical activity may interact with the effects of vitamin D on muscle function [31]. Unfortunately, we do not have available data of physical activity in our participants.

The heterogeneity in results between different studies and meta-analyses may at least to some part reflect differences in study design. It has been speculated on whether the dosing regimens might be of importance. Daily dosing has been argued to provide a more stable supply of cholecalciferol, and could act more physiologically than bolus dosing on a weekly or even more seldom basis, like used in the present study [32]. Another limitation of the present study could be that the duration of the intervention was only four months, and a longer duration may have been necessary to reveal any effects. However, for ethical reasons, it is challenging to perform long term studies including placebo groups in participants with documented vitamin D deficiency at baseline.

Also, we only measured one aspect of muscular function, namely strength, whereas endurance, power and balance were not assessed. We did, however, measure both the upper- and lower extremities, and included both proximal and distal strength. Still, it may be that we did not capture functional strength. For instance, one study among Brazilian postmenopausal women reported significant improvement in chair rising test, but no effect on handgrip strength [33].

Recently, it has been suggested that circulating levels of 1,25 dihydroxyvitamin D (1,25 $(OH)_2D$) might correlate better with muscle strength than 25(OH)D [34]. In a randomized six months trial both treatments resulted in muscle strength improvements, but administration of alphacalcidiol was significantly more effective than cholecalciferol [35]. It may therefore be that this metabolite should be taken into account. However, we did not have 1,25$(OH)_2D$ measurements available.

Finally, there were broad standard deviations in the changes in muscle strength in the treatment groups which limit the possibility of finding a significant difference in this medium-sized study. However, there were no trends in the results suggesting that this should explain the lack of effect of vitamin D.

The study also has several strengths. First, both 25(OH)D and outcomes were measured by validated methods. The participants were included based on low serum 25(OH)D

measurements. The adherence to the study and the compliance rate were high, as confirmed by the substantially increase in 25(OH)D levels in the intervention group.

To summarize, our results do not support an effect of vitamin D on muscular strength. Future studies should consider using daily dosing, including assessment of conutrient status and physical activity, and exploring use of active vitamin D in order to achieve a greater understanding of the vitamin D metabolism and musculoskeletal health.

Supporting information

S1 File. CONSORT 2010 checklist.
(DOC)

S2 File. Final protocol.
(DOCX)

Acknowledgments

Author Contributions

Conceptualization: Rolf Jorde.

Formal analysis: Guri Grimnes.

Funding acquisition: Rolf Jorde.

Investigation: Julia Kubiak, Rolf Jorde.

Methodology: Guri Grimnes, Rolf Jorde.

Project administration: Julia Kubiak, Rolf Jorde.

Writing – original draft: Guri Grimnes.

Writing – review & editing: Julia Kubiak, Rolf Jorde.

References

1. Cashman KD, Dowling KG, Skrabakova Z, Gonzalez-Gross M, Valtuena J, De Henauw S, et al. Vitamin D deficiency in Europe: pandemic? Am J Clin Nutr. 2016; 103(4):1033–1044. https://doi.org/10.3945/ajcn.115.120873 PMID: 26864360

2. Holick MF. The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol Aspects Med. 2008; 29(6):361–368. https://doi.org/10.1016/j.mam.2008.08.008 PMID: 18801384

3. Reid IR. Vitamin D effect on bone mineral density and fractures. Endocrinol Metab Clin North Am. 2017; 46(4):935–945. https://doi.org/10.1016/j.ecl.2017.07.005 PMID: 29080644

4. Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol. 2018; 6 (11):847–858. https://doi.org/10.1016/S2213-8587(18)30265-1 PMID: 30293909

5. Munns CF, Shaw N, Kiely M, Specker BL, Thacher TD, Ozono K, et al. Global consensus recommendations on prevention and management of nutritional rickets. J Clin Endocrinol Metab. 2016; 101(2):394–415. https://doi.org/10.1210/jc.2015-2175 PMID: 26745253

6. Girgis CM, Mokbel N, Cha KM, Houweling PJ, Abboud M, Fraser DR, et al. The vitamin D receptor (VDR) is expressed in skeletal muscle of male mice and modulates 25-hydroxyvitamin D (25(OH)D) uptake in myofibers. Endocrinology. 2014; 155(9):3227–3237. https://doi.org/10.1210/en.2014-1016 PMID: 24949660

7. Bischoff-Ferrari HA, Borchers M, Gudat F, Durmuller U, Stahelin HB, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res. 2004; 19(2):265–269. https://doi.org/10.1359/jbmr.2004.19.2.265 PMID: 14969396

8. Wicherts IS, van Schoor NM, Boeke AJ, Visser M, Deeg DJ, Smit J, et al. Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab. 2007; 92(6):2058–2065. https://doi.org/10.1210/jc.2006-1525 PMID: 17341569

9. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Hu FB, Zhang Y, Karlson EW, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or = 60 y. Am J Clin Nutr. 2004; 80(3):752–758. https://doi.org/10.1093/ajcn/80.3.752 PMID: 15321818

10. Yoshikawa S, Nakamua T, Tanabe H, Imamura T. Osteomalacic myopathy. Endocrinol Jpn. 1979; 26:65–72.

11. Gilsanz V, Kremer A, Mo AO, Wren TA, Kremer R. Vitamin D status and its relation to muscle mass and muscle fat in young women. J Clin Endocrinol Metab. 2010; 95:1595–601. https://doi.org/10.1210/jc.2009-2309 PMID: 20164290

12. Sinha A, Hollinsworth KG, Ball S, Cheetham T. Improving the vitamin D status of vitamin D deficient adults is associated with improved mitochondrial oxidative function in skeletal muscle. J Clin Endocrinol Metab. 2013; 98(3):E509–513. https://doi.org/10.1210/jc.2012-3592 PMID: 23393184

13. Girgis CM, Clifton-Bligh RJ, Turner N, Lau SL, Gunton JE. Effects of vitamin D in skeletal muscle: falls, strength, athletic performance and insulin sensitivity. Clin Endocrinol (Oxf). 2014; 80(2):169–81.

14. Beaudart C, Buckinx F, Rabenda V, Gillain S, Cavalier E, Slomian J, et al. The effects of vitamin D on skeletal strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2014; 99(11):4336–4345. https://doi.org/10.1210/jc.2014-1742 PMID: 25033068

15. Rosendahl-Riise H, Spielau U, Ranhoff AH, Gudbrandsen OA, Dierkes J. Vitamin D supplementation and its influence on muscle strength and mobility in community-dwelling older persons: a systematic review and meta-analysis. J Hum Nutr Diet. 2017; 30(1):3–15. https://doi.org/10.1111/jhn.12394 PMID: 27460044

16. Heaney RP. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr Rev. 2014; 72(1):48–54. https://doi.org/10.1111/nure.12090 PMID: 24330136

17. Scragg R. Limitations of vitamin D supplementation trials: Why observational studies will continue to help determine the role of vitamin D in health. J Steroid Biochem Mol Biol. 2018; 177:6–9. https://doi.org/10.1016/j.jsbmb.2017.06.006 PMID: 28627485

18. Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njolstad I. Cohort profile: the Tromsø Study. Int J Epidemiol. 2012; 41(4):961–967. https://doi.org/10.1093/ije/dyr049 PMID: 21422063

19. Kubiak J, Thorsby PM, Kamycheva E, Jorde R. Vitamin D supplementation does not improve CVD risk factors in vitamin D-insufficient subjects. Endocr Connect. 2018; 7(6):840–849. https://doi.org/10.1530/EC-18-0144 PMID: 29764903

20. Stark T, Walker B, Phillips JK, Fejer R, Beck R. Hand-held dynamometry correlation with the gold standard isokinetic dynamometry: a systematic review. Pm R. 2011; 3(5):472–479. https://doi.org/10.1016/j.pmrj.2010.10.025 PMID: 21570036

21. Thorborg K, Bandholm T, Holmich P. Hip- and knee-strength assessments using a hand-held dynamometer with external belt–fixation are inter-tester reliable. Knee Surg Sports Traumatol Arthrosc. 2013; 21(3):550–555. https://doi.org/10.1007/s00167-012-2115-2 PMID: 22773065

22. Sollid ST, Hutchinson MY, Fuskevag OM, Figenschau Y, Joakimsen RM, Schirmer H, et al. No effect of high-dose vitamin D supplementation on glycemic status or cardiovascular risk factors in subjects with pre-diabetes. Diabetes Care. 2014; 37(8):2123–2131. https://doi.org/10.2337/dc14-0218 PMID: 24947792

23. Uusi-Rasi K, Patil R, Karinkanta S, Kannus P, Tokola K, Lamberg-Allardt C, et al. A 2-year follow-up after a 2-year RCT with vitamin D and exercise: effects on falls, injurious falls and physical functioning among older women. J Gerontol A Biol Sci Med Sci. 2017; 72(9):1239–1245. https://doi.org/10.1093/gerona/glx044 PMID: 28369286

24. Levis S, Gomez-Marin O. Vitamin D and physical function in sedentary older men. J Am Geriatr Soc. 2017; 65(2):323–331. https://doi.org/10.1111/jgs.14510 PMID: 27861700

25. Ranathunga R, Hill TR, Mathers JC, Francis RM, Prentice A, Schoenmakers I, et al. No effect of monthly supplementation with 12000 IU, 24000 IU or 48000 IU vitamin D3 for one year on muscle

function: The vitamin D in older people study. J Steroid Biochem Mol Biol. 2018 pii: S0960-0760(18) 30494-1. https://doi.org/10.1016/j.jsbmb.2018.12.008 PMID: 30583082

26. Bislev SL, Lanagergaard Rødbro L, Rolighed L, Sikjaer T, Rejnmark L. Effects of vitamin D3 supplementation on muscle strength, mass, and physical performance in women with vitamin D insufficiency: a randomized placebo-controlled trial. Calcif Tissue Int. 2018; 103(5):483–493. https://doi.org/10.1007/s00223-018-0443-z PMID: 29931459

27. Wu F, Wills K, Laslett LL, Oldenburd B, Seibel MJ, Jones G, et al. Cut-points for associations between vitamin D status and multiple musculoskeletal outcomes in middle-aged women. Osteoporos Int. 2017; 116(8):505–515.

28. Liguori I, Russo G, Aran L, Bulli G, Curcio F, Della-Morte D, et al. Sarcopenia: assessment of disease burden and strategies to improve outcomes. Clin Interv Aging. 2018;26: 13:757–772. https://doi.org/10.2147/CIA.S158513 PMID: 29731617

29. Shin SC, Kim KM. Calcium, is it better to have less? Global health perspectives. J Cell Biochem. 2015; 116(8):1513–1521. https://doi.org/10.1002/jcb.25119 PMID: 25648107

30. Lips P. Interaction between vitamin D and calcium. Scand J Clin Lab Invest Suppl. 2012; 243:60–64. https://doi.org/10.3109/00365513.2012.681960 PMID: 22536764

31. Bunout D, Barrera G, Leiva L, Gattas V, de la Maza MP, Avendano M, et al. Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects. Exp. Gerontol. 2006; 41(8):746–752. https://doi.org/10.1016/j.exger.2006.05.001 PMID: 16797903

32. Jorde R, Grimnes G. Serum cholecalciferol may be a better marker of vitamin D status than 25-hydroxyvitamin D. Med Hypotheses. 2018; 111:61–65. https://doi.org/10.1016/j.mehy.2017.12.017 PMID: 29406999

33. Cangussu LM, Nahas-Neto J, Orsatti CL, Bueloni-Dias FN, Nahas EA. Effect of vitamin D supplementation alone on muscle function in postmenopausal women: a randomized, double-blind, placebo-controlles clinical trial. Osteoporos Int. 2015; 26(10):2413–2421. https://doi.org/10.1007/s00198-015-3151-9 PMID: 25956283

34. Hassan-Smith ZK, Jenkinson C, Smith DJ, Hernandez I, Morgan SA, Crabtree NJ, et al. 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 exert distinct effects on human skeletal muscle function and gene expression. PLoS One. 2017; 12(2): e0170665. https://doi.org/10.1371/journal.pone.0170665 PMID: 28199350

35. Capatina C, Caragheorgheopol A, Berteanu M, Poiana C. Short-term administration of alphacalcidiopl is associated with more significant improvement of muscular performance in women with vitamin D deficiency compared to native vitamin D. Exp Clin Endocrinol Diabetes. 2016; 124(8):461–465. https://doi.org/10.1055/s-0042-103932 PMID: 27169685